文献速递核素与放射性配体治疗

三维体素剂量学预测肝叶放射性栓塞后对侧肝增生与足够未来残肝

3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-03-05

结果显示非肿瘤治疗区平均剂量(NTL-Dmean)与NTL-V30与FLR增长相关,尤其基线FLR<30%者;当约半数NTL接受≥30 Gy时FLR可增至≥40%。

要点

  • 基线FLR<30%患者FLR随时间逐步增长,T3达44.7%。
  • NTL-Dmean与NTL-V30预测FLR增长,后者在总队列亦显著。
  • NTL中≥49%接受≥30 Gy时FLR增至≥40%,准确率76.4%。

核心结论

  • 非肿瘤治疗区剂量学参数NTL-Dmean与NTL-V30与肝叶SIRT后FLR增长显著相关,尤其在基线FLR<30%的患者中。

主要发现

  • 基线FLR<30%患者FLR从T0的25.2%逐步升至T1的32.7%、T2的38.1%、T3的44.7%。
  • 无剂量学参数预测萎缩;NTL-Dmean与NTL-V30预测基线FLR<30%患者的FLR增长,NTL-V30在总队列亦具预测性。
  • 肝增生与肿瘤剂量或肿瘤大小无显著关联。

关键数值与推荐

  • 当NTL中≥49%接受≥30 Gy时,FLR增至≥40%,全部患者准确率76.4%,基线FLR<30%患者准确率80.95%。

临床怎么用

  • 可基于90Y PET/CT体素剂量学评估NTL-V30等参数,辅助预判肝叶SIRT后FLR增长及是否具备二期切除条件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Volume changes induced by selective internal radiation therapy (SIRT) may increase the possibility of tumor resection in patients with insufficient future liver remnant (FLR). The aim was to identify dosimetric and clinical parameters associated with contralateral hepatic hypertrophy after lobar/extended lobar SIRT with 90Y-resin microspheres. MATERIALS AND METHODS: Patients underwent 90Y PET/CT after lobar or extended lobar (right + segment IV) SIRT. 90Y voxel dosimetry was retrospectively performed (PLANET Dose; DOSIsoft SA). Mean absorbed doses to tumoral/non-tumoral-treated volumes (NTL) and dose-volume histograms were extracted. Clinical variables were collected. Patients were stratified by FLR at baseline (T0-FLR): < 30% (would require hypertrophy) and ≥ 30%. Changes in volume of the treated, non-treated liver, and FLR were calculated at < 2 (T1), 2-5 (T2), and 6-12 months (T3) post-SIRT. Univariable and multivariable regression analyses were performed to identify predictors of atrophy, hypertrophy, and increase in FLR. The best cut-off value to predict an increase of FLR to ≥ 40% was defined using ROC analysis. RESULTS: Fifty-six patients were studied; most had primary liver tumors (71.4%), 40.4% had cirrhosis, and 39.3% had been previously treated with chemotherapy. FLR in patients with T0-FLR < 30% increased progressively (T0: 25.2%; T1: 32.7%; T2: 38.1%; T3: 44.7%). No dosimetric parameter predicted atrophy. Both NTL-Dmean and NTL-V30 (fraction of NTL exposed to ≥ 30 Gy) were predictive of increase in FLR in patients with T0 FLR < 30%, the latter also in the total cohort of patients. Hypertrophy was not significantly associated with tumor dose or tumor size. When ≥ 49% of NTL received ≥ 30 Gy, FLR increased to ≥ 40% (accuracy: 76.4% in all patients and 80.95% in T0-FLR < 30% patients). CONCLUSION: NTL-Dmean and NTL exposed to ≥ 30 Gy (NTL-V30) were most significantly associated with increase in FLR (particularly among patients with T0-FLR < 30%). When half of NTL received ≥ 30 Gy, FLR increased to ≥ 40%, with higher accuracy among patients with T0-FLR < 30%.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Grisanti F, Prieto E, Bastidas JF, et al. 3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization. Eur J Nucl Med Mol Imaging. 2021. PMID: 33674893. doi:10.1007/s00259-021-05272-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。